Conference Coverage

Ozanimod Is Superior to Interferon in Relapsing-Remitting MS


—Erik Greb

Suggested Reading

Cohen JA, Arnold DL, Comi G, et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(4):373-381.

Sørensen PS. Ozanimod: a better or just another S1P receptor modulator? Lancet Neurol. 2016;15(4):345-347.

Next Article:

Revised McDonald Criteria Allow Substitution for Dissemination in Time

Related Articles